ID   PAFA2_HUMAN             Reviewed;         392 AA.
AC   Q99487; D3DPK1; O15458; Q5SY02;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   28-JUN-2023, entry version 175.
DE   RecName: Full=Platelet-activating factor acetylhydrolase 2, cytoplasmic {ECO:0000303|PubMed:8955149};
DE            EC=3.1.1.47 {ECO:0000269|PubMed:9494101};
DE   AltName: Full=PAF:lysophospholipid transacetylase {ECO:0000250|UniProtKB:P83006};
DE   AltName: Full=PAF:sphingosine transacetylase {ECO:0000250|UniProtKB:P83006};
DE   AltName: Full=Platelet-activating factor acetyltransferase PAFAH2 {ECO:0000250|UniProtKB:P83006};
DE            EC=2.3.1.149 {ECO:0000250|UniProtKB:P83006};
DE   AltName: Full=Serine-dependent phospholipase A2 {ECO:0000303|PubMed:9494101};
DE            Short=SD-PLA2 {ECO:0000305};
DE            Short=hSD-PLA2 {ECO:0000303|PubMed:9494101};
GN   Name=PAFAH2 {ECO:0000312|HGNC:HGNC:8579};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8955149; DOI=10.1074/jbc.271.51.33032;
RA   Hattori K., Adachi H., Matsuzawa A., Yamamoto K., Tsujimoto M., Aoki J.,
RA   Hattori M., Arai H., Inoue K.;
RT   "cDNA cloning and expression of intracellular platelet-activating factor
RT   (PAF) acetylhydrolase II. Its homology with plasma PAF acetylhydrolase.";
RL   J. Biol. Chem. 271:33032-33038(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Prostate;
RX   PubMed=9494101; DOI=10.1042/bj3301309;
RA   Rice S.Q.J., Southan C., Boyd H.F., Terrett J.A., Macphee C.H., Moores K.,
RA   Gloger I.S., Tew D.G.;
RT   "Expression, purification and characterization of a human serine-dependent
RT   phospholipase A2 with high specificity for oxidized phospholipids and
RT   platelet activating factor.";
RL   Biochem. J. 330:1309-1315(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   REVIEW.
RX   PubMed=9218411; DOI=10.1074/jbc.272.29.17895;
RA   Stafforini D.M., McIntyre T.M., Zimmerman G.A., Prescott S.M.;
RT   "Platelet-activating factor acetylhydrolases.";
RL   J. Biol. Chem. 272:17895-17898(1997).
CC   -!- FUNCTION: Catalyzes the hydrolyze of the acetyl group at the sn-2
CC       position of platelet-activating factor (PAF) and its analogs, leading
CC       to their inactivation (PubMed:9494101). Hydrolyzes propionyl and
CC       butyroyl moieties approximately half as effectively as PAF (By
CC       similarity). Also catalyzes transacetylation of the acetyl group from
CC       platelet-activating factor (PAF) to lysoplasmalogen and to sphingosine,
CC       producing plasmalogen analogs of PAF and N-acetylsphingosine (C2-
CC       ceramide) respectively. Has a marked selectivity for phospholipids with
CC       short acyl chains at the sn-2 position (By similarity).
CC       {ECO:0000250|UniProtKB:P79106, ECO:0000250|UniProtKB:P83006,
CC       ECO:0000269|PubMed:9494101}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O-
CC         alkyl-sn-glycero-3-phosphocholine + acetate + H(+);
CC         Xref=Rhea:RHEA:17777, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707; EC=3.1.1.47;
CC         Evidence={ECO:0000269|PubMed:9494101};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17778;
CC         Evidence={ECO:0000269|PubMed:9494101};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         O-hexadecyl-sn-glycero-3-phosphocholine + acetate + H(+);
CC         Xref=Rhea:RHEA:40479, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:44811, ChEBI:CHEBI:64496;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40480;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-(1Z-alkenyl)-sn-glycero-3-phosphoethanolamine + 1-O-
CC         hexadecyl-2-acetyl-sn-glycero-3-phosphocholine = 1-O-(1Z-alkenyl)-2-
CC         acetyl-sn-glycero-3-phosphoethanolamine + 1-O-hexadecyl-sn-glycero-3-
CC         phosphocholine; Xref=Rhea:RHEA:41396, ChEBI:CHEBI:44811,
CC         ChEBI:CHEBI:64496, ChEBI:CHEBI:77288, ChEBI:CHEBI:78419;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41397;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + sphing-4-
CC         enine = 1-O-hexadecyl-sn-glycero-3-phosphocholine + H(+) + N-
CC         (acetyl)-sphing-4-enine; Xref=Rhea:RHEA:41408, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:44811, ChEBI:CHEBI:46979, ChEBI:CHEBI:57756,
CC         ChEBI:CHEBI:64496; Evidence={ECO:0000250|UniProtKB:P83006};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41409;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + a 1-
CC         organyl-2-lyso-sn-glycero-3-phospholipid = 1-O-alkyl-sn-glycero-3-
CC         phosphocholine + a 1-organyl-2-acetyl-sn-glycero-3-phospholipid;
CC         Xref=Rhea:RHEA:11048, ChEBI:CHEBI:685, ChEBI:CHEBI:30909,
CC         ChEBI:CHEBI:36707, ChEBI:CHEBI:76590; EC=2.3.1.149;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11049;
CC         Evidence={ECO:0000250|UniProtKB:P83006};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-glutaryl-sn-glycero-3-phosphocholine + H2O =
CC         1-O-hexadecyl-sn-glycero-3-phosphocholine + glutarate + H(+);
CC         Xref=Rhea:RHEA:41700, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30921, ChEBI:CHEBI:64496, ChEBI:CHEBI:78371;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41701;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-succinyl-sn-glycero-3-phosphocholine + H2O =
CC         1-O-hexadecyl-sn-glycero-3-phosphocholine + H(+) + succinate;
CC         Xref=Rhea:RHEA:41696, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30031, ChEBI:CHEBI:64496, ChEBI:CHEBI:78369;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41697;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-butanoyl-sn-glycero-3-phosphocholine + H2O =
CC         1-O-hexadecyl-sn-glycero-3-phosphocholine + butanoate + H(+);
CC         Xref=Rhea:RHEA:41692, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17968, ChEBI:CHEBI:64496, ChEBI:CHEBI:78368;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41693;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-propanoyl-sn-glycero-3-phosphocholine + H2O =
CC         1-O-hexadecyl-sn-glycero-3-phosphocholine + H(+) + propanoate;
CC         Xref=Rhea:RHEA:41688, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17272, ChEBI:CHEBI:64496, ChEBI:CHEBI:78367;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41689;
CC         Evidence={ECO:0000250|UniProtKB:P79106};
CC   -!- ACTIVITY REGULATION: Inhibited by phenylmethanesulfonyl fluoride,
CC       3,4,dichloroisocoumarin, diisopropyl fluorophosphate (DFP) and diethyl
CC       p-nitrophenyl phosphate (DENP). {ECO:0000269|PubMed:9494101}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=42 uM for 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine
CC         (PAF) {ECO:0000269|PubMed:9494101};
CC         KM=10 uM for 1-decanoyl-2-(4-nitrophenylglutaryl) phosphate (DNGP)
CC         {ECO:0000269|PubMed:9494101};
CC         Vmax=35 umol/min/mg enzyme with
CC         2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine (PAF) as
CC         substrate {ECO:0000269|PubMed:9494101};
CC         Vmax=1.7 umol/min/mg enzyme with 1-decanoyl-2-(4-nitrophenylglutaryl)
CC         phosphate (DNGP) as substrate {ECO:0000269|PubMed:9494101};
CC   -!- SUBUNIT: Monomer. {ECO:0000305|PubMed:9494101}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9494101}. Membrane
CC       {ECO:0000250|UniProtKB:P79106}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:P79106}. Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P79106}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:P79106}. Note=In resting cells, localizes to
CC       intracellular membranes and cytoplasm. Translocates from the cytoplasm
CC       to intracellular membranes upon oxidative stress.
CC       {ECO:0000250|UniProtKB:P79106}.
CC   -!- TISSUE SPECIFICITY: Broadly expressed in different tissues, but high in
CC       B- and T-lymphocytes. In brain, expression is restricted to amygdala
CC       and frontal cortex. {ECO:0000269|PubMed:8955149,
CC       ECO:0000269|PubMed:9494101}.
CC   -!- SIMILARITY: Belongs to the serine esterase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D87845; BAA13468.1; -; mRNA.
DR   EMBL; U89386; AAC39707.1; -; mRNA.
DR   EMBL; AL592064; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07852.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07853.1; -; Genomic_DNA.
DR   EMBL; BC001158; AAH01158.1; -; mRNA.
DR   CCDS; CCDS270.1; -.
DR   RefSeq; NP_000428.2; NM_000437.3.
DR   RefSeq; XP_006710733.1; XM_006710670.3.
DR   AlphaFoldDB; Q99487; -.
DR   SMR; Q99487; -.
DR   BioGRID; 111088; 16.
DR   STRING; 9606.ENSP00000363400; -.
DR   ESTHER; human-PAFAH2; PAF-Acetylhydrolase.
DR   iPTMnet; Q99487; -.
DR   PhosphoSitePlus; Q99487; -.
DR   SwissPalm; Q99487; -.
DR   BioMuta; PAFAH2; -.
DR   DMDM; 6647691; -.
DR   EPD; Q99487; -.
DR   jPOST; Q99487; -.
DR   MassIVE; Q99487; -.
DR   MaxQB; Q99487; -.
DR   PaxDb; Q99487; -.
DR   PeptideAtlas; Q99487; -.
DR   ProteomicsDB; 78290; -.
DR   Antibodypedia; 622; 159 antibodies from 23 providers.
DR   DNASU; 5051; -.
DR   Ensembl; ENST00000374282.8; ENSP00000363400.3; ENSG00000158006.14.
DR   Ensembl; ENST00000374284.5; ENSP00000363402.1; ENSG00000158006.14.
DR   GeneID; 5051; -.
DR   KEGG; hsa:5051; -.
DR   MANE-Select; ENST00000374282.8; ENSP00000363400.3; NM_000437.4; NP_000428.2.
DR   UCSC; uc001bld.4; human.
DR   AGR; HGNC:8579; -.
DR   CTD; 5051; -.
DR   DisGeNET; 5051; -.
DR   GeneCards; PAFAH2; -.
DR   HGNC; HGNC:8579; PAFAH2.
DR   HPA; ENSG00000158006; Tissue enhanced (lymphoid).
DR   MIM; 602344; gene.
DR   neXtProt; NX_Q99487; -.
DR   OpenTargets; ENSG00000158006; -.
DR   PharmGKB; PA32910; -.
DR   VEuPathDB; HostDB:ENSG00000158006; -.
DR   eggNOG; KOG3847; Eukaryota.
DR   GeneTree; ENSGT00390000005233; -.
DR   HOGENOM; CLU_022501_0_0_1; -.
DR   InParanoid; Q99487; -.
DR   OMA; MGVNQSM; -.
DR   OrthoDB; 3079661at2759; -.
DR   PhylomeDB; Q99487; -.
DR   TreeFam; TF313831; -.
DR   BRENDA; 3.1.1.47; 2681.
DR   PathwayCommons; Q99487; -.
DR   Reactome; R-HSA-418346; Platelet homeostasis.
DR   BioGRID-ORCS; 5051; 18 hits in 1159 CRISPR screens.
DR   ChiTaRS; PAFAH2; human.
DR   GeneWiki; PAFAH2; -.
DR   GenomeRNAi; 5051; -.
DR   Pharos; Q99487; Tbio.
DR   PRO; PR:Q99487; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q99487; protein.
DR   Bgee; ENSG00000158006; Expressed in body of pancreas and 130 other tissues.
DR   ExpressionAtlas; Q99487; baseline and differential.
DR   Genevisible; Q99487; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0003847; F:1-alkyl-2-acetylglycerophosphocholine esterase activity; ISS:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; TAS:ProtInc.
DR   GO; GO:0047179; F:platelet-activating factor acetyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR016715; PAF_acetylhydro_eukaryote.
DR   PANTHER; PTHR10272; PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE; 1.
DR   PANTHER; PTHR10272:SF6; PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE 2, CYTOPLASMIC; 1.
DR   Pfam; PF03403; PAF-AH_p_II; 1.
DR   PIRSF; PIRSF018169; PAF_acetylhydrolase; 1.
DR   SUPFAM; SSF53474; alpha/beta-Hydrolases; 1.
DR   PROSITE; PS00120; LIPASE_SER; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; Endoplasmic reticulum; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Lipoprotein; Membrane; Myristate; Reference proteome;
KW   Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..392
FT                   /note="Platelet-activating factor acetylhydrolase 2,
FT                   cytoplasmic"
FT                   /id="PRO_0000090383"
FT   ACT_SITE        236
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:P79106"
FT   ACT_SITE        259
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10037"
FT   ACT_SITE        314
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10037"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000250|UniProtKB:P79106"
FT   CONFLICT        212
FT                   /note="L -> F (in Ref. 2; AAC39707)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   392 AA;  44036 MW;  690FB7E6F5B68317 CRC64;
     MGVNQSVGFP PVTGPHLVGC GDVMEGQNLQ GSFFRLFYPC QKAEETMEQP LWIPRYEYCT
     GLAEYLQFNK RCGGLLFNLA VGSCRLPVSW NGPFKTKDSG YPLIIFSHGL GAFRTLYSAF
     CMELASRGFV VAVPEHRDRS AATTYFCKQA PEENQPTNES LQEEWIPFRR VEEGEKEFHV
     RNPQVHQRVS ECLRVLKILQ EVTAGQTVFN ILPGGLDLMT LKGNIDMSRV AVMGHSFGGA
     TAILALAKET QFRCAVALDA WMFPLERDFY PKARGPVFFI NTEKFQTMES VNLMKKICAQ
     HEQSRIITVL GSVHRSQTDF AFVTGNLIGK FFSTETRGSL DPYEGQEVMV RAMLAFLQKH
     LDLKEDYNQW NNLIEGIGPS LTPGAPHHLS SL
//
